We are live on
!
Find out more
X
Xponance Portfolio holdings
AUM
$14.1B
1-Year Est. Return
30.11%
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
+30.11%
3 Year Est. Return
+110.39%
5 Year Est. Return
+152.15%
10 Year Est. Return
+370.53%
AUM
$14.1B
AUM Growth
+$741M
(+5.6%)
Cap. Flow
+$1.58B
Cap. Flow
% of AUM
11.22%
Top 10 Holdings %
Top 10 Hldgs %
38.76%
Holding
1,735
New
165
Increased
1,464
Reduced
57
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$110M |
| 2 |
Apple
AAPL
|
+$89M |
| 3 |
Microsoft
MSFT
|
+$81.1M |
| 4 |
Amazon
AMZN
|
+$54.3M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$45.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Principal Financial Group
PFG
|
+$4.8M |
| 2 |
KeyCorp
KEY
|
+$4.08M |
| 3 |
SOLS
Solstice Advanced Materials
SOLS
|
+$3.06M |
| 4 |
Valero Energy
VLO
|
+$2.61M |
| 5 |
Monster Beverage
MNST
|
+$2.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.95% |
| 2 | Financials | 11.04% |
| 3 | Consumer Discretionary | 10.63% |
| 4 | Communication Services | 10.59% |
| 5 | Healthcare | 9.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
IDEAYA Biosciences
IDYA
$3.46B
| $262K | ﹤0.01% |
7,866
+1,551
| +25% | +$52K |
|
1352
Arcutis Biotherapeutics
ARQT
$3.53B
| $261K | ﹤0.01% |
11,085
+1,687
| +18% | +$43.1K |
|
1353
McGrath RentCorp
MGRC
$2.86B
| $261K | ﹤0.01% |
2,363
+386
| +20% | +$42.9K |
|
1354
Veracyte
VCYT
$4.75B
| $260K | ﹤0.01% |
8,086
+1,215
| +18% | +$45K |
|
|
UCTT
1355
Ultra Clean Holdings
UCTT
$4.71B
| $260K | ﹤0.01% |
+4,188
| New | +$215K |
|
1356
Photronics
PLAB
$1.85B
| $259K | ﹤0.01% |
+6,407
| New | +$232K |
|
1357
Nicolet Bankshares
NIC
$3.57B
| $259K | ﹤0.01% |
+1,742
| New | +$253K |
|
1358
Tarsus Pharmaceuticals
TARS
$2.5B
| $258K | ﹤0.01% |
3,684
+610
| +20% | +$42.6K |
|
1359
Provident Financial Services
PFS
$3.13B
| $258K | ﹤0.01% |
12,210
+2,021
| +20% | +$43.1K |
|
1360
Rush Street Interactive
RSI
$3.46B
| $257K | ﹤0.01% |
+11,804
| New | +$226K |
|
1361
Denali Therapeutics
DNLI
$3.78B
| $254K | ﹤0.01% |
13,240
+2,743
| +26% | +$54.6K |
|
1362
Park Hotels & Resorts
PK
$3.03B
| $254K | ﹤0.01% |
24,121
+5,730
| +31% | +$63.3K |
|
1363
Remitly
RELY
$5.02B
| $253K | ﹤0.01% |
16,132
+2,767
| +21% | +$40.9K |
|
|
USAR
1364
USA Rare Earth Inc
USAR
$3.87B
| $251K | ﹤0.01% |
+16,613
| New | +$322K |
|
1365
Unilever
UL
$131B
| $250K | ﹤0.01% |
4,396
+1,060
| +32% | +$71K |
|
1366
Oscar Health
OSCR
$9.28B
| $250K | ﹤0.01% |
21,780
+5,908
| +37% | +$83.2K |
|
|
WAY
1367
Waystar Holding Corp
WAY
$4.13B
| $250K | ﹤0.01% |
10,358
+1,657
| +19% | +$44K |
|
1368
Dr. Reddy's Laboratories
RDY
$10.5B
| $250K | ﹤0.01% |
18,021
+4,868
| +37% | +$67.8K |
|
1369
Delek US
DK
$4.12B
| $249K | ﹤0.01% |
+5,516
| New | +$197K |
|
1370
Inspire Medical Systems
INSP
$1.51B
| $248K | ﹤0.01% |
4,817
+674
| +16% | +$47.2K |
|
1371
SoundHound AI
SOUN
$2.85B
| $248K | ﹤0.01% |
36,126
+6,484
| +22% | +$56K |
|
1372
Wipro
WIT
$18B
| $248K | ﹤0.01% |
117,063
+39,076
| +50% | +$95.2K |
|
1373
Prudential
PUK
$35.7B
| $248K | ﹤0.01% |
8,727
+1,923
| +28% | +$59.2K |
|
|
HTO
1374
H2O America
HTO
$2.68B
| $247K | ﹤0.01% |
+4,204
| New | +$229K |
|
1375
InvenTrust Properties
IVT
$2.84B
| $246K | ﹤0.01% |
+8,090
| New | +$244K |
|
Similar funds
CM
ETC
BIP
FGP
BPC
SSA
TI
BBVA
Xponance's Q1 2026 Portfolio in Review
As of Q1 2026, Xponance held 1,735 positions worth $14.1B, up 5.6% from $13.3B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Xponance deployed $1.58B of net new capital in Q1 2026, opening 165 new positions and adding to 1,464 existing holdings. Its largest new stake was Medline Inc: 22,732 shares worth $1.01M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 38% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Principal Financial Group, an estimated $4.8M trimmed.
- Xponance's largest Q1 2026 buy was Medline Inc: 22,732 shares worth $1.01M.
- Xponance added most to NVIDIA in Q1 2026, an estimated $110M increase.
- Xponance's biggest Q1 2026 reduction was Principal Financial Group, cutting an estimated $4.8M.
- Xponance fully exited Confluent in Q1 2026, selling an estimated $1.34M.
- Xponance's ten largest holdings make up 39% of its $14.1B portfolio in Q1 2026.
- Xponance opened 165 new positions and closed 49 in Q1 2026.
- Xponance's portfolio value rose 5.6% quarter-over-quarter to $14.1B.
Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.